How to Buy Back a Podcaster: The Psychedelics Executive Order and the Politics of Audience Capture

A crowd gathers in Sacramento, California to protest for defending democracy with signs and American flags.

On April 18, 2026, Joe Rogan stood in the Oval Office, smiling, while President Trump signed an executive order directing federal agencies to supposedly fast-track research into psychedelic drugs. Rogan told the room how it had happened. He had texted the president information about ibogaine. The reply, he said, was “sounds great, do you want FDA approval? Let’s do it” — and he added that it was “literally that quick.”

If you had been watching American politics with any attention over the previous year, the scene was strange enough to deserve a second look.

How They Got to That Room

Rogan endorsed Trump on the eve of the 2024 election. He is widely credited with helping deliver the young male vote that turned the election. He should have been, by any normal accounting, a permanent member of the administration’s media coalition.

He was not. Beginning in mid-2025, Rogan started breaking publicly with the administration — on deportation policy, on the Epstein files, and then, most damagingly, on the war with Iran. After U.S. strikes on Iranian nuclear facilities in June 2025, Rogan said on his podcast that the war “seems so insane based on what he ran on,” and that “this is why a lot of people feel betrayed” — he ran on “no more wars” and “end these stupid, senseless wars.” By spring 2026, Rogan was openly speculating that the war had been waged on Israel’s behalf, and his audience — the same young male audience that had delivered Trump’s margin — was, polling suggested, drifting with him.

The political problem this created for the administration is not subtle. CNN reported that as many as one in four or one in five of Trump’s 2024 voters disapproved of the Iran war, and many of the rest were only lukewarm on it. Notably, Trump did not respond to Rogan’s defections the way he has responded to almost every other prominent critic. Where Rep. Thomas Massie was attacked as “not MAGA” and targeted with a primary PAC, Rogan was met with public affection. Trump called him “a fantastic person” and “a great guy.” The door was kept conspicuously open.

The psychedelics executive order is what walked through it.

What the Order Actually Does

The order’s core mechanism is to instruct the FDA to grant National Priority Vouchers to psychedelic drugs that have already received Breakthrough Therapy designation. The National Priority Voucher Program was a pilot announced in June 2025, the primary purpose of which was to dramatically reduce review times — to a one- to two-month target. It was already operating. The drugs eligible for it were already eligible.

The FDA has been granting Breakthrough Therapy designation to psychedelics for years. MDMA-assisted therapy received it in 2017. An LSD formulation received it in 2024. By the time of the executive order, the FDA had granted the designation to nearly a dozen psychedelic drugs, including Compass Pathways’ psilocybin program for treatment-resistant depression and a methylone formulation for PTSD. In the weeks after the order, three companies received the new National Priority Vouchers — two psilocybin compounds and a methylone compound — all three of which had previously received Breakthrough Therapy designation under the existing track.

In other words, the substantive acceleration the order is credited with had been underway, through existing programs, for years.

The genuinely novel piece is narrower. The order directs the FDA and DEA to establish a separate pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds, that are under FDA review. Ibogaine — unlike psilocybin, MDMA, and LSD — does not yet have Breakthrough Therapy designation. It also carries documented cardiac risk and has been linked to more than 30 deaths in the medical literature. The investigational access pathway is essentially an ibogaine ramp dressed in the language of a broader psychedelics initiative.

This matters because ibogaine is the specific substance Rogan has championed publicly for years.

The Audience Underneath

The other thing the executive order does is appeal directly to a demographic the administration cannot afford to lose: the loose coalition that supported RFK Jr., now Secretary of Health and Human Services, and that voted in 2024 partly on the promise of dismantling pharmaceutical orthodoxy. Polling has found that about 69% of MAHA supporters approve of Kennedy’s job performance, and the coalition includes about one in five Democrats — voters not durably attached to either party. Reporting suggests the White House views the MAHA constituency as significant enough that firing Kennedy, despite tensions, has been viewed as politically too costly.

This is the same audience that has been receptive to psychedelics, ivermectin, raw milk, and the general project of reframing FDA caution as suppression. It is also, substantially, the audience that listens to Joe Rogan.

An executive order on psychedelics threads a single needle through three constituencies: the Rogan audience, the RFK/MAHA audience, and the veterans’ advocacy networks that have been pushing for ibogaine access. CMS Administrator Mehmet Oz said the order was written in less than a week, and that “the president just would not take no for an answer.” Speed of that kind is rarely about policy. It is about timing.

How It Resolved

The photo op did its work. Within a week, the major news cycles had absorbed the image of Rogan smiling in the Oval Office, of Trump and Kennedy and a Navy SEAL agreeing on something hopeful for veterans. Whether the order produces any measurable change in the timelines for psychedelic approval — beyond what was already happening — will take years to determine.

It did not, however, repurchase Rogan. Days after the signing, on his next major episode, Rogan was back on the Iran war: “Why did we do it? I don’t know, I think because of Israel, if I had to guess.” He questioned whether the U.S. had any exit strategy at all. The criticism resumed. The pictures, however, were already in circulation.

This is what political audience capture looks like at the highest level: a major piece of executive action shaped, in part, around the management of a single podcaster’s relationship to the administration. The substance was mostly ratification of policy that was already in motion. The function was to make sure that a man with the largest audience in American media stood in the Oval Office, smiling, on the news that day.

By that measure, the order was a success. It just was not, in any meaningful sense, a psychedelics policy.